UnitedHealth Group Incorporated (NYSE:UNH - Get Free Report) Director Timothy Patrick Flynn purchased 1,533 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were bought at an average price of $320.80 per share, for a total transaction of $491,786.40. Following the acquisition, the director now owns 6,033 shares in the company, valued at $1,935,386.40. This trade represents a 34.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
UnitedHealth Group Stock Performance
Shares of NYSE UNH traded up $18.77 during mid-day trading on Friday, reaching $293.12. 56,876,207 shares of the company were exchanged, compared to its average volume of 5,806,444. UnitedHealth Group Incorporated has a twelve month low of $248.88 and a twelve month high of $630.73. The stock has a market capitalization of $265.90 billion, a P/E ratio of 18.80, a P/E/G ratio of 1.37 and a beta of 0.56. The company's 50-day simple moving average is $474.72 and its 200-day simple moving average is $515.82. The company has a quick ratio of 0.91, a current ratio of 0.83 and a debt-to-equity ratio of 0.74.
UnitedHealth Group (NYSE:UNH - Get Free Report) last announced its earnings results on Thursday, April 17th. The healthcare conglomerate reported $7.20 EPS for the quarter, missing the consensus estimate of $7.29 by ($0.09). The business had revenue of $109.58 billion for the quarter, compared to the consensus estimate of $111.56 billion. UnitedHealth Group had a return on equity of 26.69% and a net margin of 3.60%. During the same period in the prior year, the business posted $6.91 earnings per share. As a group, research analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.
UnitedHealth Group Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 18th. Stockholders of record on Monday, March 10th were paid a $2.10 dividend. The ex-dividend date of this dividend was Monday, March 10th. This represents a $8.40 annualized dividend and a dividend yield of 2.87%. UnitedHealth Group's payout ratio is 35.18%.
Institutional Trading of UnitedHealth Group
Several large investors have recently bought and sold shares of UNH. NewSquare Capital LLC acquired a new stake in shares of UnitedHealth Group during the 4th quarter valued at $25,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in UnitedHealth Group during the 4th quarter worth approximately $26,000. Hurley Capital LLC bought a new position in shares of UnitedHealth Group during the fourth quarter valued at $28,000. Bayforest Capital Ltd grew its stake in shares of UnitedHealth Group by 685.7% in the first quarter. Bayforest Capital Ltd now owns 55 shares of the healthcare conglomerate's stock worth $29,000 after purchasing an additional 48 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in UnitedHealth Group in the fourth quarter valued at approximately $30,000. 87.86% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Mizuho dropped their price target on UnitedHealth Group from $515.00 to $350.00 and set an "outperform" rating on the stock in a research note on Friday. StockNews.com raised UnitedHealth Group from a "hold" rating to a "buy" rating in a report on Thursday, January 23rd. Cantor Fitzgerald reissued an "overweight" rating and set a $700.00 price objective on shares of UnitedHealth Group in a report on Friday, January 17th. Truist Financial dropped their price target on UnitedHealth Group from $660.00 to $580.00 and set a "buy" rating for the company in a research report on Monday, April 21st. Finally, Argus cut shares of UnitedHealth Group from a "buy" rating to a "hold" rating in a research report on Monday, April 21st. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $486.00.
Read Our Latest Stock Analysis on UNH
About UnitedHealth Group
(
Get Free Report)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.